



# Sterne Kessler Goldstein Fox

Patrick J. Gaffney  
Jeffrey J. Gaffney  
Theo J. Gaffney  
John Gaffney  
Edward W. Gaffney  
Albert Gaffney  
John J. Gaffney  
William Gaffney  
Albert Gaffney  
John Gaffney  
Albert Gaffney  
Edward Gaffney  
W. Russell Gaffney  
Thomas J. Gaffney  
Brian J. Gaffney  
J. G. Beaumont  
Reginald Beaumont

Nancy Leeth  
Joseph M. Conrad  
A. L. Schmittner and  
John C. Clegg  
David J. Givens  
Matthew J. W. Williams  
A. R. H. Edwards  
A. J. McLean and  
Peter A. Matthes  
Mark E. Jung  
Katherine P. Peacock  
John P. Kotek  
Joseph E. Goss  
A. L. M. Cho

APR 19 2007

April 18, 2002

**WRITER'S DIRECT NUMBER:**  
(202) 371-2560

*INTERNET ADDRESS:*  
resmond@skgf.com

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 09/937,484; § 371 Date: January 23, 2002  
For: **Use of a Leetin or Conjugates for Modulation of C-Fibre Activity**  
Inventors: Foster *et al.*  
Our Ref: 1581.0870000/RWE/MIT

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. Form PTO-1449 and accompanying reference;
3. Certificate Under 37 C.F.R. § 3.73(b), with copy of Assignment attached (which was erroneously returned to the undersigned together with the recorded Assignment) to be made of record in the application file; and
4. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
April 18, 2002  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

RWE/dab  
Enclosures

SKGE DCT 44771



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Foster *et al.*

Appl. No. 09/937,484

§ 371 Date: January 23, 2002

For: **Use of a Lectin or Conjugates for  
Modulation of C-Fibre Activity**

Confirmation No. 2134

Art Unit: (to be assigned)

Examiner: (to be assigned)

Atty. Docket: 1581.0870000/RWE/MTT

RECEIVED  
APR 19 2002  
TECH CENTER 1600/2900

**First Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on September 26, 2001, in connection with the above-captioned application. A copy of the document is also provided.


Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of the cited document and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: April 18, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600



APR 13 2002  
FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1581.0870000/RWE/MTT

APPLICATION NO.  
09/937,484

APPLICANTS  
Foster et al.

5371 DATE  
January 23, 2002

GROUP  
(to be assigned)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						RECEIVED
	AB						
	AC						APR 19 2002
	AD						
	AE						TECH CENTER 1600 2900
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Bizzini, R., "Investigation of the Mode of Action of Tetanus Toxin With the Aid of Hybrid Molecules Consisting in Part of Tetanus Toxin-Derived Fragments," in <i>Bacterial Protein Toxins</i> , Academic Press London, pp. 427-434 (1984)
	AS	2	
	AT	7	

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.